Abstract
Immune thrombocytopenia (ITP) is an autoimmune disease characterized by the decrease of platelet count. In recent years, the pathogenesis, diagnosis and treatments of adult ITP have achieved significant progress. In particular, with wide clinical applications of rituximab, thrombopoietin (TPO) and TPO receptor agonist (TPORA) in ITP, the second-line treatment options have no longer limited to splenectomy. This article mainly discusses the second-line treatment options of adult ITP after first-line treatments failure, in order to provide individualized treatments. Key words: Thrombocytopenia; Adult; Splenectomy; Rituximab; Thrombopoietin; Thrombopoietin receptor agonist
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
